ImmPACT: uniting CAR T platforms for ‘logic-gate’ therapies

With three “logic gate-based” platforms designed to address shortcomings of other CAR T approaches, ImmPACT Bio has won the backing of a VC syndicate led by venBio for a $111 million series B round to advance a lead bispecific CAR T program that’s already generating responses in a clinical study.

ImmPACT Bio USA Inc. raised the round under the leadership of a new president and CEO, Sumant Ramachandra, who was chief science, technology and medical officer at Baxter International Inc. (NYSE:BAX) and president of its Baxter Global Pharmaceuticals division. Joining the company as board chair is Sheila Gujrathi, the co-founder and former CEO of Gossamer Bio Inc. (NASDAQ:GOSS) and former CMO at Receptos Inc. before its 2015 buyout by Celgene Corp., now part of Bristol Myers Squibb Co. (NYSE:BMY)...